UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

Journal of clinical oncology, 2021-12, Vol.39 (35), p.3959-3977

2021

Volltextzugriff (PDF)

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1124-1130

2010

Volltextzugriff (PDF)

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (8), p.1301-1307

2010

Volltextzugriff (PDF)

American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

Journal of clinical oncology, 2010-08, Vol.28 (23), p.3784-3796

2010

Volltextzugriff (PDF)

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Journal of clinical oncology, 2008-04, Vol.26 (11), p.1810-1816

2008

Volltextzugriff (PDF)

Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease

Journal of clinical oncology, 2008-02, Vol.26 (5), p.814-819

2008

Volltextzugriff (PDF)

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

Journal of clinical oncology, 2011-08, Vol.29 (24), p.3328-3330

2011

Volltextzugriff (PDF)

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Journal of clinical oncology, 2008-04, Vol.26 (12), p.1993-1999

2008

Volltextzugriff (PDF)

Aromatase inhibitor-associated arthralgia syndrome

Breast (Edinburgh), 2007-06, Vol.16 (3), p.223-234

Burstein, Harold J

2007

Volltextzugriff (PDF)

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

Cancer, 2007-09, Vol.110 (5), p.965-972

2007

Volltextzugriff (PDF)

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

Cancer, 2003-06, Vol.97 (12), p.2972-2977

2003

Volltextzugriff (PDF)

American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays

Journal of clinical oncology, 2004-09, Vol.22 (17), p.3631-3638

2004

Volltextzugriff (PDF)

Past, present, and future challenges in breast cancer treatment

Journal of clinical oncology, 2014-07, Vol.32 (19), p.1979-1986

2014

Volltextzugriff (PDF)

Chemotherapy for Metastatic Breast Cancer

Hematology/oncology clinics of North America, 2007-04, Vol.21 (2), p.257-272

2007

Volltextzugriff (PDF)

Multidisciplinary considerations in the treatment of triple‐negative breast cancer

CA: a cancer journal for clinicians, 2020-11, Vol.70 (6), p.432-442

2020

Volltextzugriff (PDF)

Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era

Breast (Edinburgh), 2013-08, Vol.22 (4), p.525-531

2013

Volltextzugriff (PDF)

Off-label use of oncology drugs: too much, too little, or just right?

Journal of the National Comprehensive Cancer Network, 2013-05, Vol.11 (5), p.505-506

Burstein, Harold J

2013

Volltextzugriff (PDF)

Neoadjuvant pertuzumab: the exception that proves the rule?

Oncology (Williston Park, N.Y.), 2014-03, Vol.28 (3), p.197-199

Burstein, Harold J

2014

Volltextzugriff (PDF)

A "shot heard 'round the world" on cancer drug costs?

Journal of the National Comprehensive Cancer Network, 2012-11, Vol.10 (11), p.1315-1316

Burstein, Harold J

2012

Volltextzugriff (PDF)

Trastuzumab: qui bono?

JNCI : Journal of the National Cancer Institute, 2013-12, Vol.105 (23), p.1772-1775

2013

Volltextzugriff (PDF)

Deep time: the long and the short of adjuvant endocrine therapy for breast cancer

Journal of clinical oncology, 2012-03, Vol.30 (7), p.684-686

2012

Volltextzugriff (PDF)

Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy

Journal of clinical oncology, 2009-12, Vol.27 (34), p.5671-5673

2009

Volltextzugriff (PDF)

Take your medicine

Journal of the National Comprehensive Cancer Network, 2011-02, Vol.9 Suppl 3 (Suppl_3), p.S1

Burstein, Harold J

2011

Volltextzugriff (PDF)

Cognitive side-effects of adjuvant treatments

Breast (Edinburgh), 2007, Vol.16, p.166-168

Burstein, Harold J

2007

Volltextzugriff (PDF)

Beyond Tamoxifen — Extending Endocrine Treatment for Early-Stage Breast Cancer

The New England journal of medicine, 2003-11, Vol.349 (19), p.1857-1859

Burstein, Harold J

2003

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Aktive Filter

ThemaChemotherapy

ThemaAntineoplastic Agents - Therapeutic Use

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(34)

Sprache

Englisch
(34)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Aromatase inhibitor-associated arthralgia syndrome

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays

Past, present, and future challenges in breast cancer treatment

Chemotherapy for Metastatic Breast Cancer

Multidisciplinary considerations in the treatment of triple‐negative breast cancer

Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era

Off-label use of oncology drugs: too much, too little, or just right?

Neoadjuvant pertuzumab: the exception that proves the rule?

A "shot heard 'round the world" on cancer drug costs?

Trastuzumab: qui bono?

Deep time: the long and the short of adjuvant endocrine therapy for breast cancer

Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy

Take your medicine

Cognitive side-effects of adjuvant treatments

Beyond Tamoxifen — Extending Endocrine Treatment for Early-Stage Breast Cancer

Aktive Filter

Suchergebnisse filtern